Literature DB >> 9403756

Perflubron decreases inflammatory cytokine production by human alveolar macrophages.

M J Thomassen1, L T Buhrow, H P Wiedemann.   

Abstract

OBJECTIVE: To determine whether inflammatory cytokine production by stimulated human alveolar macrophages is affected by perflubron exposure.
DESIGN: Controlled laboratory investigation of alveolar macrophage function in vitro.
SETTING: Research laboratory.
SUBJECTS: Cultured alveolar macrophages obtained by bronchoalveolar lavage from eleven normal volunteers.
INTERVENTIONS: Endotoxin-stimulated alveolar macrophages were treated with perflubron.
MEASUREMENTS AND MAIN RESULTS: Alveolar macrophages were stimulated for 1 hr with lipopolysaccharide and then treated with perflubron for 23 hrs. Cell-free supernatants were collected and cytokines were assayed by enzyme-linked immunosorbent assay. Tumor necrosis factor-alpha, interleukin-1, and interleukin-6 were stimulated by lipopolysaccharide (endotoxin) and all of these cytokines were significantly (p < .05) inhibited by perflubron. Cell viability was not affected by perflubron. Basal cytokine concentrations from unstimulated alveolar macrophages were not altered by perflubron.
CONCLUSIONS: Exposure of stimulated human alveolar macrophages to perflubron in vitro decreases cytokine production. This observation suggests that perflubron may have anti-inflammatory activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9403756     DOI: 10.1097/00003246-199712000-00023

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  7 in total

1.  Inhibition of inflammatory responses by FC-77, a perfluorochemical, in lipopolysaccharide-treated RAW 264.7 macrophages.

Authors:  Hung Chang; Fu-Chang Kuo; Yuan-Shu Lai; Tz-Chong Chou
Journal:  Intensive Care Med       Date:  2005-06-02       Impact factor: 17.440

2.  High vapor pressure perfluorocarbons cause vesicle fusion and changes in membrane packing.

Authors:  Berenice Venegas; Marla R Wolfson; Peter H Cooke; Parkson Lee-Gau Chong
Journal:  Biophys J       Date:  2008-08-08       Impact factor: 4.033

3.  Infectious and inflammatory dissemination are affected by ventilation strategy in rats with unilateral pneumonia.

Authors:  Frédérique Schortgen; Lila Bouadma; Marie-Laure Joly-Guillou; Jean-Damien Ricard; Didier Dreyfuss; Georges Saumon
Journal:  Intensive Care Med       Date:  2004-01-22       Impact factor: 17.440

4.  Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin.

Authors:  Ryan A Orizondo; Charlene Irvin Babcock; Mario L Fabiilli; Leonid Pavlovsky; J Brian Fowlkes; John G Younger; Keith E Cook
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-01-29       Impact factor: 2.849

5.  Effect of exogenous surfactants on viability and DNA synthesis in A549, immortalized mouse type II and isolated rat alveolar type II cells.

Authors:  Andreas Wemhöner; Paul Jennings; Thomas Haller; Mario Rüdiger; Georg Simbruner
Journal:  BMC Pulm Med       Date:  2011-02-17       Impact factor: 3.317

6.  Systemic administration of FC-77 dampens ischemia-reperfusion-induced acute lung injury in rats.

Authors:  Shi-Jye Chu; Kun-Lun Huang; Shu-Yu Wu; Fu-Chang Ko; Geng-Chin Wu; Rui-Ying Li; Min-Hui Li
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

7.  Perfluorochemical (PFC) liquid enhances recombinant adenovirus vector-mediated viral interleukin-10 (AdvIL-10) expression in rodent lung.

Authors:  John T Li; Laura A Bonneau; Jerry J Zimmerman; Daniel J Weiss
Journal:  J Inflamm (Lond)       Date:  2007-05-01       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.